Advanced search
Publication Cover
Infectious Diseases Volume 51, 2019 - Issue 6
Submit an article Journal homepage
96
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Is it time to re-think the use of etravirine in patients with available genotypic resistance test?

Filippo Del PuenteClinic of Infectious Diseases, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy;Correspondence[email protected]
,
Niccolo’ RiccardiClinic of Infectious Diseases, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy;
,
Lucia TaramassoClinic of Infectious Diseases, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy;;Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy;
,
Alberto BorghettiIstituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy;
,
Alessandro D’AvinoOspedale Generale “Cristo Re”, Rome, Italy;
,
Sara Irene BonelliUO Malattie Infettive – Ospedale San Jacopo, Pistoia, Italy;
,
Andrea De LucaInfectious Diseases Unit, AOU Senese, Siena, Italy;;
,
Maurizio ZazziInfectious Diseases Unit, AOU Senese, Siena, Italy;;
&
Antonio Di BiagioDepartment of Internal Medicine, Clinic of Infectious Diseases, Policlinico San Martino Hospital, Genoa, Italy
 show all
Pages 452-455 | Received 01 Dec 2018, Accepted 08 Jan 2019, Published online: 30 Apr 2019

References

  • Eriksen J, Albert A, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infect Dis (London). 2017;49:1–34.
  • Tseng A, MacArthur R. Profile of etravirine for the treatment of HIV infection. Ther Clin Risk Manag. 2010;6:49–58.
  • Nelson M, Hill A, van Delft Y, et al. Etravirine as a Switching Option for Patients with HIV RNA Suppression: a review of recent trials. AIDS Res Treat. 2014;2014:636584.
  • Yazdanpanah Y, Fagard C, Descamps D, ANRS 139 TRIO Trial Group, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49:1441–1449.
  • HIV Drug Resistance Database [Internet]. Hivdb.stanford.edu. 2018 [cited 5 June 2018]. Available from: https://hivdb.stanford.edu
  • Ribaudo H, Lennox J, Currier J, et al. Virologic failure endpoint definition in clinical trials: Is using HIV-1 RNA threshold < 200 copies/mL better than < 50 copies/mL? An analysis of ACTG studies. Presented at: Conference on Retroviruses and Opportunistic Infections. 2009; Montreal, Canada.
  • Arathoon E, Bhorat A, Silaghi R, et al. Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE Open Med. 2017;5:205031211668648.
  • Orkin C, Squires KE, Molina JM, et al. DRIVE-AHEAD Study Group. doravirine/lamivudine/tenofovirdisoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2018. doi:10.1093/cid/ciy540. [Epub ahead of print] PubMed PMID: 30184165.
  • Tambuyzer L, Azijn H, Rimsky LT, et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2009;14:103–109. doi:10.1093/cid/ciy540. [Epub ahead of print] PubMed PMID: 30184165.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.